PSMD2

Across TCGA pan-cancer cohorts, PSMD2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of PSMD2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PSMD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PSMD2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, LUSC, and LIHC are the cancer types where PSMD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PSMD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+1.626	<.001	12	view →
LUSC	Female	All	+1.940	<.001	9	view →
LIHC	Female	II,III,IV	+1.559	<.001	9	view →
BLCA	All	All	+0.842	<.001	9	view →
LUAD	All	III,IV	+0.748	<.001	9	view →
COAD	Female	All	+0.496	<.001	9	view →
STAD	All	II,III,IV	+0.886	<.001	6	view →
BRCA	All	II,III,IV	+0.648	<.001	6	view →
CHOL	Male	All	+2.281	<.001	5	view →
KIRC	Female	All	+0.346	.002	5	view →
UCEC	All	II,III,IV	+0.897	.002	4	view →
KIRP	Female	II,III,IV	+0.456	.011	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

PSMD2–HNSC

Open the HNSC breakdown →